Disclosed is a method of treating pancreatic cancer in an individual in need thereof comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising a taxane and an albumin, wherein the individual has progressed on a gemcitabine-based therapy. The pancreatic cancer is recurrent, resistant or refractory pancreatic cancer. The treatment can occur after at least 6 months after prior therapy, such as gemcitabine-based therapy. The therapy can be a mono-therapy or a combination therapy with another chemotherapeutic agent such as vandetanib.
